Genomic Disruption of VEGF-A Expression in Human Retinal Pigment Epithelial Cells Using CRISPR-Cas9 Endonuclease
Investigative Ophthalmology & Visual Science2016Vol. 57(13), pp. 5490–5490
Citations Over TimeTop 10% of 2016 papers
Abstract
The CRISPR-Cas9 endonuclease system may reduce VEGF-A secretion from human RPE cells and suppress angiogenesis, supporting the possibility of employing gene editing for antiangiogenesis therapy in ocular diseases.
Related Papers
- → Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy(2018)93 cited
- → Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field(2017)52 cited
- → Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On‐ and Off‐Target Damage(2020)20 cited
- → [Research progress of CRISPR-Cas9 system for gene therapy].(2016)6 cited
- → Prediction of off-target effects of the CRISPR/Cas9 system for design of sgRNA(2020)